|
|
Quantity change and clinical significance of myeloid-derived suppressor cells in peripheral blood of the patients with gastric cancer |
WU Zhi-dan1,2, WANG Sheng-jun1 |
(1 School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2.Clinical Laboratory, Jiangyin Hospital Affiliated to Southeast University School of Medicine, Jiangyin Jiangsu 214400, China) |
|
|
Abstract Objective: To explore the quantity change and significance of myeloid-derived suppressor cells(MDSCs)in peripheral blood of the patients with gastric cancer.Methods : Twenty-four patients with gastric cancer were enrolled in this study, collected preoperative peripheral blood 2 mL. And fifteen healthy volunteers were done so too.Selected patients 30 days after operation and restored smoothly 18 cases to be checked,and matched with preoperative data.Collected the peripheral blood and the factors of CD14-/CD11b+/CD33+/HLA-DR- were taken as marks of MDSCs.Analysed the changes of MDSCs number and clinical significance of the proportion using flow cytometry(FCM). At the same time,analyzed the relationship between the expression of MDSCs in peripheral blood and clinical pathological factors.Results: MDSCs in peripheral blood of healthy controls accounted for (0.226±0.044)%,MDSCs proportion of gastric cancer patients with preoperative and postoperative checking in peripheral blood were (1.903±0.247)% and (1.120±0.240)% respectively.The MDSCs proportion difference in gastric cancer pantients and control group was statistically significant(P<0.05),and the MDSCs proportion before and after surgery had significant difference too. MDSCs in the peripheral blood of patients with gastric cancer associated with the degree of tumor differentiation, had nothing to do with gender,age,tumor size, depth of invasion,TNM staging and with or without lymph node metastasis.Conclusions: MDSCs play an important role in gastric cancer patients with immune dysfunction.The bodys antitumor immune function had been some restored after cutting down tumor burden.
|
Received: 06 March 2013
|
|
|
|
[1]OstrandRosenberg S.Myeloidderived suppressor cells:more mechanisms for inhibiting antitumor immunity[J].Cancer Immunol Immunother,2010,59(10):1593-1600.[2]Gabrilovich DI,Nagaraj S.Myeloidderived suppressor cells as regulators of the immune system[J].Nat Rev Immunol,2009,9(3):162-174.[3]Ilkovitch D,Lopez DM.The liver is a site for tumor, induced myeloidderived suppressor cell accumulation and immunosuppression[J]. Cancer Res,2009,69(13):5514-5521.[4]Serafini P,Borrello I,Bronte V.Myeloid suppressor cells in cancer:recruitment, Phenotype properties,and mechanisms of immune suppression[J].Semin Cancer Biol,2006,16(1):55-65.[5]Sinha P,Okoro C,Foell D,et al.Proinflammtory S100 proteins regulate the accumulation of myeloidderived suppressor cells[J].Immunol,2008,181(7):4666-4675.[6]Srivastava MK,Sinha P,Clements VK,et al.Myeloidderived suppressor cells inhibit Tcell activation by depleting cystine and cysteine[J].Cancer Res,2010,70(1):68-77.[7]Tabata T,Hazama S,Yoshino S,et al.Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers[J].Am J Surg,1997,177(3):203-208.[8]孔琦,朱家胜,芮景.Th1/Th2偏移与肿瘤免疫研究进展\[J\].现代肿瘤医学,2010,18(8):1653-1655.[9]Bunt SK,Sinha P,Clements VK,et al.Inflammation induces myeloidderived suppressor cells that facilitate tumor progression[J]. J Immunol, 2006,176 (1):284-290. |
|
|
|